Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin plus ruxolitinib in myelofibrosis with suboptimal response to ruxolitinib
2024-514468-26-00Phase 2Authorised
- Sponsor
- Kartos Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of navtemadlin and ruxolitinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Kartos Therapeutics. Primary endpoints: Dose-limiting toxicities and determination of MTD/RP2D and Spleen volume response at Week 24. Planned start Dec 2020; status: authorised.
02
Drugs
navtemadlinruxolitinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2024-514468-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514468-26-00.